RE:RE:RE:RE:RE:RE:RE:RE:Glaring Mismatch…Dom I think the buyout could be in the not too distant future because 1) actions suggest no exit via NASDAQ listing as it hasn't been done in 2 years and 2) Baxter is happy - maybe all they had to do was take PMX to this stage in the Tigris trial - EDEN is new and likely at Baxter's request - and DIMI is being stalled for some reason - the redacted agreement could shed light here but is hidden from public shareholders and 3) the newly published time lines (2023 sometime folks) suggest there's still complex work ahead whether there is or not and 4) management has boatloads of fresh and new equity on a string at low prices - pick the fruit when it's ripe rather than waiting in case it starts to rot - game changing amounts of money for the anointed ones.
Optics are way better if a US major (Baxter) completes and gets FDA approvals rather than a small and unknown Canadian company getting the glory and holding the valuable keys. While I love the thought of a 30 bagger and do feel it's FMV my estimate is closer to a 20 bagger from these engineered low share price levels. That's so it looks correct for two unfinished projects. All speculation of course.